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SUMMARY 
Targeted proteomic methods can accelerate the verification of multiple tumor marker candidates 
in large series of patient samples. We utilized the targeted approach known as selected / multiple 
reaction monitoring (SRM/MRM) to verify potential protein markers of colorectal adenoma 
identified by our group in previous transcriptomic and quantitative shotgun proteomic studies of 
a large cohort of precancerous colorectal lesions. We developed SRM assays to reproducibly 
detect and quantify 25 (62.5%) of the 40 selected proteins in an independent series of 
precancerous and cancerous tissue samples (19 adenoma/normal mucosa pairs; 17 
adenocarcinoma/normal mucosa pairs). Twenty-three proteins were significantly upregulated 
(n=17) or downregulated (n=6) in adenomas and/or adenocarcinomas, as compared with normal 
mucosa (linear fold changes ≥ ±1.3, adjusted P value <0.05). Most changes were observed in 
both tumor types (upregulation of ANP32A, ANXA3, SORD, LDHA, LCN2, NCL, S100A11, 
SERPINB5, CDV3, OLFM4, and REG4; downregulation of ARF6 and PGM5), and a five-
protein biomarker signature distinguished neoplastic tissue from normal mucosa with a 
maximum area under the receiver operating curve greater than 0.83. Other changes were 
specific for adenomas (PPA1 and PPA2 upregulation; KCTD12 downregulation) or 
adenocarcinoma (ANP32B, G6PD, RCN1, and SET upregulation; downregulated AKR1B1, 
APEX1, and PPA1). Some changes significantly correlated with a few patient- or tumor-related 
phenotypes. Twenty-two (96%) of the 23 proteins have a potential to be released from the 
tumors into the bloodstream, and their detectability in plasma has been previously reported. The 
proteins identified in this study expand the pool of investment-worthy biomarker candidates that 
can be used to develop a standardized pre-colonoscopy blood test for the early detection of 
colorectal tumors.  
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INTRODUCTION 
Colorectal malignancies are a major driver of cancer-related morbidity and mortality in 
adults (1, 2). Most of these cancers originate as benign, adenomatous lesions of the colorectal 
mucosa. (3-5). Although they are noninvasive, colorectal adenomas already harbor genetic and 
epigenetic alterations that disrupt the homeostatic equilibrium between proliferation, 
differentiation, and apoptosis (particularly those involving components of the Wnt-APC-
βcatenin pathway). With time, however, some adenomas acquire additional mutations that result 
in their transformation. Colorectal adenomas and early-stage adenocarcinomas can be eradicated 
with ease, and the prognosis in these cases is generally good (2, 6, 7).  
Early detection is thus the best way to reduce the incidence of colorectal cancer (CRC). 
Major progress on this front has been hampered, however, by the limitations of available 
screening techniques (8-10). Colonoscopy offers high diagnostic accuracy and allows prompt 
removal of suspicious early-stage lesions, but endoscopic screening is invasive, costly, and 
time-consuming. Fecal assays have none of the latter drawbacks, but their specificity is low, and 
they are reportedly less effective in the detection of adenomas than of adenocarcinomas (10-12).  
One of the most promising solutions for filling this diagnostic gap involves the use of 
targeted proteomic methods to identify and quantify tumor-associated proteins in body fluids. 
Major ongoing advances in proteomics technology are providing researchers with methods that 
are more sensitive and reproducible than data-dependent techniques (13-16). Selected reaction 
monitoring (SRM)—also known as multiple reaction monitoring (MRM)—is a sensitive 
targeted proteomic technique for the reproducible quantification of specific proteins within a 
complex sample background (14, 17, 18). Importantly, in a single SRM experiment, numerous 
precursor/fragment ion pairs (i.e., transitions), and therefore several proteins can be monitored 
across a relatively large number of samples. The resulting chromatographic trace provides 
information on the retention time and signal intensity per transition, which can be used to 
determine the relative or absolute abundance of several target peptides. If results are normalized 
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to a defined amount of a stable isotope-labeled internal peptide, endogenous protein abundance 
can also be compared in various samples and/or under diverse test conditions (17, 19, 20).  
Proteomic studies have already pinpointed several potential biomarker candidates for the 
detection of CRC. However, most studies stop short of verifying the candidates in a systematic 
and reproducible manner, an essential step for translating biomarker discoveries to clinical 
application (6, 8, 9, 21). Verification, however, is an arduous process, which is made even more 
difficult by the lack of appropriate tools for identifying and reproducibly quantifying levels of 
candidate proteins across multiple samples (6, 21). Enzyme-linked immunosorbent assays 
(ELISAs) are still the preferred methods for preclinical verification of candidate biomarkers, but 
the antibodies used for these assays are characterized by high specificity requirements and 
elevated production costs, which render them less than ideal for testing large numbers of tumor 
biomarkers (19, 22). Targeted proteomic techniques have been proposed as standard 
complementary methods for the clinical verification and validation of candidate disease 
biomarkers, and these methods are being used in an increasing number of clinical proteomic-
based cancer studies (19, 23-33). 
In a comprehensive shotgun proteomics study of human colorectal adenomas and patient-
matched samples of normal colon mucosa, we recently identified several putative diagnostic 
markers representing tumor stages along the adenoma-adenocarcinoma pathway (34). In the 
present study, we developed targeted SRM assays (27) and used them to profile the expression 
of these candidate protein markers in a large, independent group of colorectal tumors, 
precancerous and invasive. The results revealed potential markers that significantly 
distinguished CRC tumors from healthy tissues, showed substantial correlation with clinical 
parameters and are apparently detectable in human plasma. 
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EXPERIMENTAL PROCEDURES  
Human tissue samples 
Tissue samples were used with local ethics committee approval and in conformity with 
the principles set forth in the Declaration of Helsinki. Human colorectal tissues were collected 
prospectively during colonoscopies performed at the Instituti Ospitalieri of Cremona, Italy. All 
donors provided written consent to sample collection, testing, and data publication. Samples 
were identified by numerical codes to protect donors’ rights to confidentiality. The series 
comprised 19 adenomas and 17 adenocarcinomas, each with a matched sample of normal 
mucosa from the colon segment bearing the tumor (>2 cm from the lesion). The characteristics 
of the paired normal and tumor tissue samples are summarized in Table 1. Immediately after 
collection, samples were frozen in liquid nitrogen and stored at -80°C. 
Protein extraction from tissues 
Rapidly weighed frozen tissue samples (weight range: 10 to 70 mg) were placed in 
solution (180 µl) containing 100 mM triethylammonium bicarbonate (Sigma, St. Louis, MO, 
USA), 1X Complete Ethylenediaminetetraacetic acid (EDTA)-free Protease Inhibitor Cocktail 
(Roche, Mannheim, Germany), 1 M urea, 5 mM β-glycerophosphate disodium salt hydrate, 1 
mM sodium orthovanadate, and 5 mM sodium fluoride (Sigma, St Louis, MO, USA) and 
homogenized on ice in a Wheaton glass borosilicate grinder. The homogenate was transferred to 
a 1.5-ml Eppendorf tube, the grinder was washed with 60 µl of lysis buffer, and the combined 
volumes were sonicated with a Bioruptor (Diagenode, Denville, NJ, USA) (high power, five 
10''/10'' ON/OFF cycles) and centrifuged (16,000 g for 5 min at 4°C). The supernatant 
containing the tissue protein extract was collected and stored at -80°C. 
Protein digestion  
For each sample, 50 micrograms of protein in denaturing buffer (initial reaction volume 
= 62.5 µl in 4M Urea) were reduced with 10 mM dithiothreitol (1.25 µl of a 500-mM stock 
solution) at 35°C for 45 min and alkylated with 50 mM iodoacetamide (6.4 µl of a 500-mM 
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stock solution) at room temperature for 1 h in the dark. Dithiothreitol (50 mM: 7 µl of a 500-
mM solution) was added to terminate the alkylation reaction, and the samples were incubated at 
room temperature for 10 min. Afterwards, 5 µl of 0.1 µg/µl sequencing-grade endoproteinase 
Lys-C (Roche, Mannheim, Germany) was added to each sample and incubated at room 
temperature for 3 h. After Lys-C digestion, the samples were diluted with 50 mM ammonium 
bicarbonate to a final urea concentration of 1.4 M, and digested with 2.5 µl of 0.4 µg/µl 
sequencing-grade modified trypsin (Promega, Madison, WI, USA) at 37°C for 15 h. To stop the 
digestion, we added acetonitrile and trifluoroacetic acid (TFA) to a total concentration of 3% 
acetonitrile and 0.1% TFA, and pH 2 - 3. The pH of acidified samples was verified with pH-
indicator strips (McolorpHastTM, Merck, KGaA, Darmstadt, Germany). Compared with in-
solution trypsin digestion, serial proteolysis using Lys-C and trypsin increases the yield of fully 
cleaved peptides, thereby improving the accuracy and sensitivity of SRM protein quantification 
(35). Peptide solutions were desalted on SepPak C18 columns, lyophilized in a vacuum 
centrifuge, and resolubilized in 50 μl (1:1 v/w) of a solution of 3% acetonitrile, 0.1% formic 
acid, and indexed Retention Time (iRT) 10X Mix (Biognosys AG, Zurich, Switzerland) (36). 
The iRT mix was prepared in accordance with the manufacturer's protocol. 
Stable isotope-labeled standard peptides (heavy peptides) for SRM assay library 
Isotope-labeled heavy peptides corresponding to the proteotypic peptides selected for the 
study (Supplementary Table 1), and containing either a C-terminal [13C(6) 15N(4)] arginine or 
a [13C(6) 15N(2)] lysine residue were purchased from JPT Peptide Technologies GmbH 
(Berlin, Germany). A pool containing known quantities of each standard peptide in the sample 
matrix solution was subjected to nano-liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis carried out on an LTQ Orbitrap Velos (Thermo Fischer Scientific, Bremen, 
Germany). Mascot output .dat files were imported into Skyline (37) and used to generate the 
spectral library for SRM transitions.  
SRM assay development and time-scheduled SRM analysis 
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The SRM assay was developed on a TSQ Vantage Triple Quadrupole Mass Spectrometer 
(Thermo Fischer Scientific, Bremen, Germany) using a sample mixture containing defined 
amounts of each isotope-labeled peptide and data from the spectral library. The spectral library 
consisted of transitions measured in data-independent mode in the sample mixture. A 
preliminary SRM-transition list for at least two peptides per protein was created from the 
spectral library in Skyline. For each peptide, we selected four to eight dominant transitions 
(precursor and most intense fragment ion pair) consisting of doubly and triply charged y- and b-
ion precursors (2+ and 3+ charge states), and fragment ions with charge states of 1+ and 2+. 
Peptides were analyzed on the TSQ Vantage in the SRM mode, which involves repeated cycling 
through a list of transitions, with pre-defined dwell-times on each transition (17). Retention 
times extracted from the SRM scans were used to calculate iRT values (36) for each peptide in 
Skyline. SRM scans were searched to confirm the near absence of endogenous transitions in the 
crude peptide mix.  We selected transitions with optimum SRM properties (14, 17) and iRT 
values for defining time-scheduled SRM methods to monitor our target proteins. In time-
scheduled SRM mode, the full cycle time is used to detect and quantify peptides expected to 
elute within a given retention-time window. This restricts the acquisition of defined transitions 
to a window around the elution time of the corresponding peptide. We optimized SRM 
parameters, including collision energy (CE), as previously described (38), dwell time, and crude 
peptide spike-in amount. Retention time scheduling for all transitions was selected based on 
Skyline scheduling predictions. A window of ± 2.5 min was used to schedule all transitions. The 
final transition list consisted of 600 transitions. To facilitate the detection of low-abundance 
peptides without compromising the dwell time of 0.020 s per transition, the 600 transitions were 
divided into two groups of 300 (based on protein name) and analyzed with two different time-
scheduled SRM acquisition methods (Method 1, Method 2). Complete information on the two 
groups of transitions is provided in Supplementary Tables 2 and 3. Two proteins (GAPDH 
and HSP90AA1) generally used as “housekeeping” proteins were included in our protein target 
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list to explore their utility as global standards in colorectal tissues, but they were not used to 
normalize the intensities of target transitions. SRM transitions for these proteins and iRT 
peptides were monitored in each method. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)  
Scheduled SRM measurements were performed on the TSQ Vantage instrument 
equipped with a nanoelectrospray ionization source and coupled to a NanoLC Ultra 2D HPLC 
system (Eksigent Technologies, Dublin, CA, USA). The instrument was used in the SRM 
acquisition mode with the following settings: Q1 resolution, 0.7 FWHM Q3 resolution, 0.7 
fwhm; cycle time, 2 s. A spray voltage of 1.3 keV was used with an ion transfer tube set heated 
to a temperature of 270°C. Argon was used as the collision gas at a nominal pressure of 1.5 
mTorr. Chromatographic separation of peptides was performed on a frit column (150 mm x 75 
μm) made in-house and coupled to a fused silica emitter (100 mm x 75 μm) (New Objective 
Inc., Woburn, MA, USA). The columns were packed with reverse-phase C18 material (AQ, 3 
μm 200 Å, Bischoff GmbH, Leonberg, Germany) and maintained at 50°C with an automatic 
heater during all SRM experiments. Peptides were loaded onto the column from a cooled (4°C) 
Eksigent autosampler and separated with a linear gradient of acetonitrile/water containing 0.1% 
formic acid at a flow rate of 300 nl/min. An elution gradient of 5% to 35% acetonitrile over 60 
min was used. Four microliters of sample, corresponding to 1.25 μg peptide mass, was injected. 
Blank runs were performed between SRM measurements of paired biological samples to avoid 
sample carryover.   
Sample randomization and blocking 
Our experimental design employed a block-randomized sample strategy (39). As shown 
in Figure 1, the order in which the adenoma/normal mucosa and adenocarcinoma/normal 
mucosa pairs were analyzed was determined randomly, and balanced allocation in each group 
was maintained during both the sample preparation and SRM analysis phases. Proteins were 
extracted from four tissue samples at a time (i.e., 1 adenoma/normal mucosa pair and 1 
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adenocarcinoma/normal mucosa pair). For the digestion of the protein extracts, we divided the 
36 sample pairs into three groups. One sample pair randomly selected from each group was 
digested twice to control for unwanted variations in peptide intensity at this step of sample 
preparation. As a result, the total number of samples for scheduled SRM analysis increased from 
72 to 78. The order of spectral acquisition on the TSQ Vantage was also randomized. For each 
SRM method (Figure 1), we created a sample queue using the random function in Microsoft 
Excel. Samples were randomized based on protein digestion group, protein extraction pairs, day 
of sample processing, and SRM data acquisition. Each patient sample was analyzed with both 
time-scheduled methods, thus producing 156 acquired data files. Sample analysis time was 270 
h, including run times for iRT and blank controls. SRM data was statistically analyzed to detect 
differences between the adenoma and normal mucosa groups and between the adenocarcinoma 
and normal mucosa groups.  
Data analysis 
SRM data were analyzed as outlined in Figure 1. Peak group identification and peptide 
scoring were performed using mProphet, a computational tool for statistically validating SRM 
mass spectrometry data (40), in SpectroDive software (Version 5.5.5478.20997, Biognosys AG, 
Zurich, Switzerland). Input files for this analysis consisted of the data files containing the SRM 
spectra acquired for each sample during the scheduled runs and the transition assay list detailing 
specified parameters such as Q1, Q3, CE, iRT score and relative fragment intensity 
(Supplementary Table 4). SpectroDive processes SRM data using the assay list of target and 
heavy standard peptides and applies mProphet’s extraction and scoring strategy. mProphet 
employs a ”decoy-transition” approach to probabilistically score individual features in SRM 
peaks and integrates them into a combined discriminant score (Cscore) while controlling for the 
false discovery rate (FDR) (40). Decoy transitions are transitions for peptide species that are 
known to be absent in the biological sample; they therefore function as negative controls. We 
employed synthetic decoys because our workflow involved the use of isotope-labeled internal 
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standards (Supplementary Table 4). Peptides that were detected in at least 6 samples and had an 
FDR <1% corresponding to a Cscore >10 were further processed for quantification 
(Supplementary Table 5).  
Protein significance was analyzed with the MSstats R-package (MSstats.daily 2.1.6) in R 
statistical software (version 3.2.3) (41). The input file for this analysis contained values for 
Condition, Bioreplicate, and Run, as pre-assigned in Skyline according to the experimental 
design (Supplementary Tables 6 and 7). Data were first processed in MSstats, and all 
transition intensities were transformed into log2 values. Next, normalization based on 
“equalizeMedians” (41) was performed on all transitions using the transition intensities of the 
isotope-labeled standard peptides. This equalized the median of standard intensities across runs 
and applied similar between-run shifts to endogenous peptide intensities in the experiment. 
Quantification of protein abundance and analysis of differential abundance in patient groups 
were performed with the linear mixed effect model for SRM workflows utilizing stable isotope-
labeled standard peptides (41, 42) to normalize the intensities of respective endogenous 
peptides. The resulting P values were corrected for multiple comparisons (41). Significant 
tumor-associated dysregulation was defined as differential expression in neoplastic (adenoma 
and/or adenocarcinoma) and normal mucosa characterized by an adjusted P value of <0.05 and a 
linear fold change ≥ ±1.3 (corresponding to a log2 fold change of 0.4).  
Statistical and functional network analysis 
Protein abundance ratios (endogenous/isotope-labeled standard) were visualized using 
the TreeView software (43). The pROC package in R was used to generate receiver operating 
characteristics (ROC) curves and to calculate areas under the curves (AUCs) and corresponding 
confidence intervals. The 95% confidence interval of the AUC was computed with 2000 
stratified bootstrap replicates for each case. Relationships between protein abundance and 
clinical variables were assessed with linear models (lm) using single stratum analysis of 
variance (ANOVA) (categorical variables) or regression (numerical variables) analysis, both 
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performed in R. Intraclass correlation coefficients (ICC) (44) were calculated in R statistical 
software to assess the agreement between protein expression changes measured with SRM and 
those obtained in our previous study (34) with iTRAQ (isobaric tags for relative and absolute 
quantification) methods. Deconvoluted protein ratios were calculated to compare SRM- and 
iTRAQ-based measurements on the same scale. The deconvoluted protein ratios (e.g. normal 
mucosa vs. adenoma or adenoma vs. normal mucosa) derived from SRM measurements were 
calculated as the ratio of endogenous peptide (L) to heavy peptide (H) in each normal mucosa vs 
adenoma pair (i.e. normal L/normal H : adenoma L/adenoma H). Deconvoluted iTRAQ protein 
ratios for normal mucosa vs. adenoma were calculated as previously described (34). 
Functional network analysis to identify potential interaction partners was performed with 
the GeneMANIA algorithm (genemania.org). The methods used for weighting and for analyzing 
network associations were automatically selected in GeneMANIA. Bar plots and dot plots were 
prepared in GraphPad Prism (version 6). Protein association with diseases was examined using 
the web version of FunDO (45). Briefly, the disease association of each gene in the genome was 
annotated using the Disease Ontology and peer-reviewed evidence from GeneRIF (46). A 
condensed version of the Disease Ontology, Disease Ontology Lite, was used for the statistical 
analysis (47), and the significance of each disease association was evaluated by Fisher's exact 
test (48). 
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RESULTS 
SRM assays for verification of candidate colorectal tumor markers 
We performed an independent validation study to verify findings from our earlier 
discovery-based transcriptomic (49) and shotgun proteomic (34) studies of a large cohort of 
precancerous colorectal lesions. Our objective was to create a high-throughput SRM-based 
workflow for detecting and quantitating the relative abundance of candidate biomarkers in an 
independent series of colorectal adenomas. We also examined colorectal adenocarcinomas to 
validate protein abundance changes during tumor progression. The characteristics of the 19 
adenomas and 17 adenocarcinomas analyzed are listed in Table 1. Protein abundance in each 
tumor was normalized to that found in patient-matched samples of normal mucosa. The 40 
target proteins selected for this study (Supplementary Table 1) included: 29 candidate 
biomarkers of colorectal neoplasia identified in our previous shotgun proteomics study (34); six 
proteins putatively involved in the same or related pathways as some of these 29 proteins; three 
candidate biomarkers of colorectal neoplasia identified in a previous transcriptomic study by our 
group (49); and two proteins widely used as housekeeping proteins (GAPDH and HSP90AA1). 
Proteotypic peptide sequences for each protein were selected based on the results of our 
previous study (34), and from other proteomics data sets available in the Peptide Atlas database 
(50). Additionally, peptide sequences conformed with empirical selection criteria including the 
length of the tryptic peptide sequence, hydrophobicity, uniqueness, and absence of missed 
cleavages (17, 51, 52). When possible, we also avoided the use of sequences with amino acids 
prone to chemical modification.  This selection resulted in a total of 140 proteotypic peptides, 
with a minimum of two peptides per protein (Supplementary Table 1). 
Targeted SRM assays for the 40 selected proteins in unfractionated extracts were developed 
and optimized as illustrated in Supplementary Figure 1 (see also Experimental Section). 
Although sample fractionation improves sensitivity when combined with shotgun-proteomic 
workflows, it is less useful in SRM workflows (23, 53). The additional sample preparation steps 
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increase the chances of variation in the measurement of protein abundance. The sample 
throughput level also declines because multiple fractions from each sample have to be measured 
individually.  
Stable isotope-labeled heavy standard peptides with amino-acid sequences identical to those 
of the corresponding 140 endogenous peptides were synthesized and analyzed by LC-MS/MS to 
validate the peptide sequence. This step was necessary to ensure confident identification of each 
peptide monitored, to compensate for suppression effects, and to improve measurement 
precision (27). Spectral libraries were generated in Skyline with data acquired by shotgun 
analysis of a mixture of pooled aliquots of the 140 crude synthetic peptides.  
Of the 140 peptides analyzed, only 74, corresponding to 31 proteins (Supplementary 
Table 8), were detected.  Nondetection of the other peptides may have been related to several 
factors, including suboptimal MS ionization properties and/or matrix effects caused by other 
components in the unfractionated samples.  
Targeted analyses of colorectal tissue samples by LC-SRM 
The optimized SRM assays were used to quantify 31 target proteins in colorectal tissue 
samples. Tissue peptide digests were assayed in randomized order (Figure 1). Equal amounts of 
each standard peptide were introduced into each tissue peptide sample from a pooled mixture of 
74 standard peptides. Standard isotope-labeled peptides were used as internal controls during 
statistical analysis of our SRM data and for the measurement of relative changes in protein 
abundance across tissue samples. Each tissue peptide digest also contained a known 
concentration of a mixture of iRT reference peptides (36), which served as internal controls for 
monitoring instrument and technical variations during time-scheduled SRM measurements. 
Based on precursor and fragment ion intensities, two to four transitions were selected for each 
standard (heavy) and endogenous (light) peptide.  
Reproducibility of SRM measurements 
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The sensitivity and validity of SRM measurements can be affected by pre-analytical 
variability (introduced by factors such as sample preparation) and/or analytical variability 
(resulting from undesirable variation of instrument parameters during SRM data acquisition) 
(19). Our block-randomized (39) study design (Figure 1, explained in Experimental Procedures) 
ensured adequate sample randomization from the processing phase through SRM spectral 
acquisition. The paired feature (normal and tumor) of colorectal tissue for each patient was 
maintained in our randomized design. We examined our SRM data for unwanted bias caused by 
variability in instrument performance.  
As shown in Supplementary Figure 2, a retention time shift of less than 1 min was 
maintained for each iRT peptide in all samples analyzed by time-scheduled SRM. Although 
each tissue sample was analyzed with both time-scheduled methods, chromatographic 
performance remained stable across all 156 SRM measurements. 
The reproducibility of our SRM spectral peak measurements for each peptide was also 
assessed by comparing the endogenous (light) to standard (heavy) peptide (L/H) peak ratios for 
each peptide monitored in duplicate peptide digests from the same protein extract. As shown in 
Figure 1, protein extracts from three paired samples of normal and tumor tissues (total: 6 
samples) were digested twice, and the resulting 12 digests were analyzed separately on the mass 
spectrometer, applying a randomized SRM sequence. For each duplicate pair, an R2 value of 
>0.9 and an intercept of ~1 was observed, indicating that a reproducible peak area was obtained 
for all peptides measured in each sample duplicate (Supplementary Figure 3). This 
demonstrates that the confounding effects of instrument variance on our data and the inferred 
results were adequately minimized.  
Peptide identification and quantification of protein abundance in colorectal tissues 
Confident identification of peptides in the 72 tissue peptide digests analyzed was 
achieved using the mProphet statistical tool (40). A comprehensive list of peptide identification 
parameters is provided in Supplementary Table 5. Peptides were considered identified if peak 
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groups had a Cscore (40) >10 at a controlled FDR (Qvalue) cutoff of <1%. Applying this 
stringent cutoff (Supplementary Table 5), we identified 53 endogenous peptides and achieved a 
sensitivity of 71.5% in peak group selection. Moreover, we manually confirmed the co-elution 
of heavy and light peptides for these 53 peptides. 
A peptide peak group was chosen for protein quantification only if the corresponding 
standard synthetic peptide transitions were observed in peptide digests from all 72 tissue 
samples analyzed. The 39 peptides that fulfilled this requirement were used to quantify 25 
proteins. Overall, the SRM assays developed and refined in the present study to quantify 
selected proteins in colorectal tissues achieved a success rate of 62.5% (25 out of 40 proteins) 
(Figure 2A and Supplementary Figure 4).  
SRM verification of putative biomarkers for colorectal neoplasia 
Our SRM assays successfully detected 25 of the 40 candidate protein biomarkers in 
unfractionated digests of the tissue proteome. We subsequently confirmed that these assays 
could be used to reproducibly quantify levels of those 25 proteins across tumor samples and to 
identify their differential abundance between tumor and normal mucosa samples. All 25 proteins 
were reliably quantified across samples (Figure 2B). Statistical analysis to identify significantly 
dysregulated proteins was performed with MSstats (41, 42), as described in Experimental 
Procedures. Proteins with an adjusted P value of <0.05 and a fold change ≥ ±1.3 were 
considered significantly altered (Figure 3). One of the housekeeping proteins, GAPDH, 
displayed significantly different abundance level in adenomas and normal mucosa samples after 
the data were normalized with heavy peptides (equalizedMedians option in MSstats, see 
Experimental Procedures). Therefore, normalizing data to "housekeeping" proteins did not 
appear to be a reliable method for maximizing quantification of colorectal tumor-related protein 
variations in this study.  
Seventeen proteins showed significant differences in abundance in colorectal adenoma 
versus normal mucosa samples (Figure 3A, and Table 2). ANP32A, ANXA3, SORD, GAPDH, 
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LDHA, LCN2, NCL, S100A11, SERPINB5, CDV3, PPA1, PPA2, OLFM4, and REG4	   were 
upregulated in adenoma versus normal mucosa samples. By contrast, expression levels of 
ARF6, KCTD12, and PGM5 were significantly reduced in adenoma samples.  
Marked adenocarcinoma-related alterations were observed in the expression of 20 
proteins: ANP32A, ANP32B, ANXA3, SORD, G6PD, LDHA, LCN2, NCL, S100A11, 
SERPINB5, CDV3, OLFM4, RCN1, REG4 and SET were significantly upregulated, and 
AKR1B1, ARF6, APEX1, PPA1, and PGM5 were significantly downregulated relative to 
normal mucosa samples (Figure 3B, and Table 2)  
The diagnostic potential of the five most markedly dysregulated proteins (selected on the 
basis of P values) in each tumor type was assessed using ROC analysis on protein intensity 
ratios (L/H). Figure 4 depicts the trade-off between sensitivity and specificity for five adenoma-
associated proteins (S100A11, SORD, SERPINB5, NCL, and PGM5) with AUC values ≥0.87. 
A similar analysis of adenocarcinoma samples yielded AUC values >0.80 for SERPINB5, 
ARF6, ANXA3, CDV3, and NCL, indicating a fairly good capacity for distinguishing cancer 
lesions from normal mucosa (Figure 5). 
In summary, most of the proteins whose expression levels were significantly altered in 
tumor samples showed directionally similar forms of dysregulation (as compared with normal 
mucosa) in both adenomas and adenocarcinomas (Table3, Supplementary Figure 5): 11 of 
these proteins (ANP32A, ANXA3, SORD, LDHA, LCN2, NCL, S100A11, SERPINB5, CDV3, 
OLFM4, REG4) were significantly upregulated, while expression levels of ARF6, and PGM5 
were decreased in both tumor types. However, some proteins showed significant expression 
changes in only one of the two tumor types: upregulation of PPA1 and PPA2 and 
downregulation of KCTD12 were seen exclusively in adenomas, whereas upregulation of 
ANP32B, G6PD, RCN1, and SET and downregulation of AKR1B1, APEX1, and PPA1 were 
specific to adenocarcinomas. In approximately 80% of both types of tumors the direction of 
dysregulation (increased or decreased protein levels) (r = 0.77, P value = 0.001) was the same in 
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both tumor groups. PPA1 was an exception, displaying higher-than-normal abundance in 
adenomas and lower-than-normal abundance in carcinomas (Supplementary Figures 5 and 6). 
In a combined ROC analysis using adenoma and adenocarcinomas as a single classifier (i.e., 
neoplastic tissue), a panel of five proteins (S100A11, SERPINB5, NCL, SORD and ANXA3) 
discriminated between normal mucosa and neoplastic tissue with sensitivity ranging from 70% 
to 100% at 80% specificity (Figure 6).  
We investigated the correlation (P values and Pearson’s r score) between the abundance 
of these five proteins and different clinical features of the tumors using linear models for 
regression analysis or ANOVA (see Experimental Procedures). As shown in Figure 7, SORD 
and NCL levels in adenomas and cancers tend to be higher in larger lesions (panel A). 
Furthermore, levels of SORD, S100A11 and SERPINB5 were more positively correlated with 
adenoma-associated mucosal pit patterns (IIIs, IIIl and IV) and histology (TA, TVA, VA) than 
with cancer-associated pit pattern (type V) and histology (panels B and C, respectively) (3). 
When correlation analysis was extended to all the proteins that were significantly dysregulated 
in adenomas and/or cancers, PGM5 and G6PD levels displayed significant correlation with 
patient age, while SET, AKR1B1 and PPA2 abundance showed significant correlations with 
tumor size based on P values (Supplementary Figures 7). Furthermore, an array of proteins 
outlined in Supplementary Figure 8 significantly associated with tumor mucosal pit pattern, 
tumor histology and colon segment where tumor was localized (Table 2). 
SRM-based measurements of the selected 23 proteins were in general consistent with 
corresponding figures obtained with iTRAQ technology in our previous study in another 
adenoma series (34): ICC (A,1) = 0.65, P value = 0.00010, 95% CI = 0.353 – 0.828. We also 
calculated the Pearson’s correlation coefficient between SRM and iTRAQ measurements using 
the average deconvoluted normal vs. adenoma ratio for each protein (see Experimental 
Procedures for explanation of protein deconvoluted ratios). A Pearson’s r-value of 0.82 showed 
a positive correlation between both datasets (Figure 8A).  However, few iTRAQ changes were 
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not validated by SRM. The upregulation of APEX1, RCN1 and SET observed with iTRAQ in 
adenomas were not confirmed by SRM, but they were detected in the adenocarcinomas analyzed 
by SRM (Figure 3). ARF6 levels were upregulated in the adenomas analyzed by iTRAQ and 
downregulated in the adenomas of the present study (Figure 8A). To explore this discrepancy, 
we recalculated the protein abundance ratio of ARF6 in the iTRAQ adenomas—first using the 
sum of reporter ion channels from all confidently identified peptides (34), then with reporter ion 
intensity from the unique peptide employed for SRM quantification (Supplementary Table 8)—
and compared the resulting deconvoluted protein ratios with the one from the SRM study 
(Figure 8B). As expected, ARF6 protein ratio based on all peptides confidently identified by 
iTRAQ indicated upregulation in adenomas, whereas that based solely on the proteotypic 
peptide employed for SRM quantification showed a similar regulation trend with no significant 
change in expression from that of normal mucosa. This inconsistency in iTRAQ and SRM 
measurements for ARF6 might be attributed to biological variance inherent to patient samples. 
The adenoma-related downregulation of ARF6 detected in the patient samples examined by 
SRM is most likely accurate since this protein is even more substantially downregulated in 
adenocarcinomas (Figure 3 and Table 2), and its expression is positively correlated with a more 
advanced (type V) mucosal pit pattern (Figure 8C and Table 2).  
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DISCUSSION 
This study demonstrates that SRM technique can be used to quantify levels of multiple 
proteins that are putative markers of colorectal neoplasia across a relatively large set of tissue 
samples. In the assay we developed, tissue protein extracts could be analyzed without being 
subjected to sample fractionation or depletion of high-abundance proteins. Randomization and 
blocking were incorporated into the experimental design to maximize the chances of detecting 
true quantitative differences between normal and neoplastic (adenomas or carcinomas) 
colorectal tissues. Thanks to their high reproducibility, our sample preparation and SRM 
measurement protocols (Supplementary Figures 2 and 3) can be readily adapted for use in 
various laboratories. Our panel of five proteins displaying tumor-associated dysregulation 
predicted the presence of both precancerous and invasive colorectal tumors.  
The fact that our SRM assays failed to quantify 12 of the 40 proteins we targeted might 
be related to the detection limit we set for low-abundance proteins in our unfractionated, 
complex samples (54, 55), since it was higher than that used for fractionated peptide digests in 
our previous study (34). It is also possible that the endogenous proteotypic peptides we selected 
to represent these proteins had suboptimal MS signal responses. Despite these shortcomings, our 
experience in this study clearly highlighted the advantages of targeted proteomics platforms 
over the shotgun (or discovery) MS methods (e.g, iTRAQ) used in our previous study (34)), 
which include higher quantitative sensitivity, improved reproducibility, and multiplex 
capabilities (56). The emerging targeted MS methods, Sequential Window Acquisition of all 
Theoretical Spectra (SWATH) and Parallel Reaction Monitoring, may well provide even more 
comprehensive proteome profiles and further expand the degree of multiplexing achieved with 
SRM (14-16).  
The proteotypic peptides targeted by SRM are selected a priori to facilitate 
differentiation between protein isoforms or proteins with shared peptides. In addition, the 
targeted peptide and fragment ions are reproducibly monitored in all samples, which improves 
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selectivity (14, 17, 57). In our previous shotgun MS study (34), for example, adenoma-
associated expression changes in LDH, ANP32, and PPA could not be attributed to a specific 
isoform of the enzymes because similar peptides were used for the relative quantification of 
both isoforms (LDHA vs. LDHB, ANP32A vs. ANP32B, and PPA1 vs. PPA2). In the present 
study, we chose peptides that were unique to each protein/isoform and thus obtained isoform-
specific information on the altered abundance of these enzymes in colorectal tumors (Table 2 
and Supplementary Figure 9).  
 On the whole, SRM-based measurements of the proteins of interest displayed good 
agreement and correlation with corresponding figures obtained with an 8-plex iTRAQ approach 
(Figure 8A). The main outlier was ARF6, which displayed reduced adenoma-related expression 
in the present study while iTRAQ analysis had revealed increased levels in the precancerous 
tumors. This inconsistency mainly reflects heterogeneity in ARF6 expression across the patient 
tumors examined. It is not wholly related to the use of one unique peptide for SRM 
quantification of ARF6 since the reported expression trend for this protein in the iTRAQ cohort 
did not change when protein intensity was recalculated based on only this peptide (Figure 8B). 
Moreover, SRM measurements based on the unique peptide for ARF6 demonstrated adenoma-
related downregulation of this protein in an independent cohort, which was supported by the 
positive correlation with more severe mucosal changes (Figure 8C) and progression to cancer 
(Figure 3).   
Compression of signal intensity ratios secondary to co-isolation and fragmentation of 
tagged precursors is a known drawback of iTRAQ labeling (58-60). Others include under-
sampling due to stochastic selection of precursor ions and intensity-biased selection of precursor 
ions (59, 60). All of these phenomena can cause variability across samples in protein 
identification and quantification (17, 61), underscoring once again the need for more sensitive 
and reproducible methods such as SRM for the validation of potential biomarker candidates. 
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Regular colonoscopic screening is recommended for individuals with age-related risk 
factors for CRC. The reported sensitivity of this approach ranges from 89% to 98% for the 
detection of adenomas 10 mm or larger and from 75% to 93% for those measuring 6 mm or 
more (62). Colonoscopy rarely misses adenomas 10 mm or larger (2.1%), but miss rates 
increase with smaller adenomas (63). In addition, the efficacy of colonoscopic screening 
programs is often reduced by low patient participation rates (64, 65). Efforts have thus been 
made to find cheaper, noninvasive alternatives that can detect both CRC and advanced 
precancerous lesions (i.e., >10 mm large adenomas) with high sensitivity, thereby improving 
patient compliance and clinical outcomes. The past decade has witnessed the discovery of a 
number of potential biomarkers for the diagnosis of colorectal neoplasms (6, 66, 67), but the 
only non-invasive screening methods for CRC approved thus far involve immunoassays for 
fecal hemoglobin (68). Studies are underway to assess the efficacy of a more recently developed 
multi-target stool DNA test, which combines hemoglobin detection with quantitative molecular 
assays for KRAS mutation, β-actin, and aberrant NDRG4 and BMP3 methylation (68). In a large 
cross-sectional validation study on asymptomatic individuals at average risk for CRC, this new 
approach detected significantly more cancers than the fecal immuno test, but it also yielded 
more false-positive results. Its sensitivity for the detection of advanced adenomas—admittedly 
mediocre (42.4%)—was clearly higher than that of the fecal immuno test (23.8%).  
Unlike DNA, protein-based markers provide an accurate representation of the functional 
cellular conditions being investigated and are fundamental for the phenotypic diagnosis of a 
disease. For example, mutation of a gene might affect different domains of the protein it 
encodes, resulting in diverse phenotypes. Furthermore, DNA aberrations generated by double-
strand breaks can be amplified into a variety of protein modification events. However, assays for 
measuring protein levels in fecal samples are not as well established as stool DNA assays in 
spite of reports that stool samples from patients with CRC can be distinguished from those of 
controls based on levels of several tumor-derived proteins, including pyruvate kinase M2 (69, 
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70), carcinoembryonic antigen (CEA) (70), secreted clusterin isoform (71), and 
minichromosome maintenance proteins (72). The application of proteomics to the analysis of 
stool samples has been hindered by the biological processes involving partial digestion and 
decay of proteins throughout the gastrointestinal tract, as well as by technical challenges related 
to sample preservation and processing.   
Disease-specific eukaryotic protein markers enter the extra-cellular space via 
conventional and/or unconventional secretory pathways (73). Proteins with signal peptides are 
usually secreted through conventional pathways involving the endoplasmic reticulum-Golgi 
system.  Unconventional secretory pathways include [1] translocation across the plasma 
membrane, [2] lysosome-dependent pathways, and [3] extracellular vesicles-dependent secretion 
(74). We examined probable secretion pathways for the 23 candidate proteins.  
First, the SignalP server 4.0 (75) was used to identify protein(s) that possessed a signal 
peptide and were actively secreted via the classical pathway, while the SecretomeP server 2.0a 
(76) was used to predict protein secretion via non-classical pathways for proteins with or 
without signal peptides (Table 2). At a Discrimination score (D-score) cutoff ≥0.45, NGAL, 
OLFM4, RCN1 and REG4 are most likely secreted via the classical pathways. Four additional 
proteins (APEX1, ARF6, S100A11 and KCTD12) were predicted by SecretomeP (Neural 
Network output or NN-score ≥0.60) to undergo non-classical secretion.  
Second, because non-classical secretion of proteins can also occur via their 
externalization in extra-cellular vesicles (e.g., microvesicles, exosomes, and apoptotic bodies), 
we analyzed our candidates using Vesiclepedia (77), a manually curated compendium of 
molecules identified in different classes of extracellular vesicles. Surprisingly, all our candidate 
proteins have been detected in microvesicles and exosomes from colorectal cells (Table 2). 
Tumor cells can also be shed into the blood. Since extracellular vesicles and circulating tumor 
cells can be robustly and reproducibly detected in blood and other body fluids, it seems 
reasonable to expect that our candidate protein biomarkers are potentially detectable in blood 
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(78).  This conclusion is supported by the fact that 61% of our target proteins (Table 2) were 
found in the high-confidence human plasma proteome reference set reported by Farrah and 
colleagues (79), and 96% (all except OLFM4) were present in the largest high-confidence 
plasma proteome dataset available to date, that generated by Keshishian and colleagues using a 
novel plasma-based biomarker discovery workflow that increased sample throughput and 
improved the depth of proteome identification and relative quantification (80). Leakage into the 
blood stream of proteins from early-stage adenomas is probably unlikely given the small size of 
these tumors and the barriers the proteins would have to circumvent prior to reaching the blood. 
There is a higher chance of detecting proteins from advanced adenomas or adenocarcinomas in 
the plasma/serum due to leakage, shedding or protein secretion. For example, studies on one of 
our candidate biomarkers, SERPINB5, confirmed that levels of this protein are increased in 
serum from patients with colorectal adenomas or adenocarcinomas, as compared with healthy 
individuals (81). 
Certain molecular changes associated with tumor occurrence and progression can be 
observed in multiple types of cancer and even in certain chronic inflammatory diseases. Their 
detection in body fluids might thus be fairly nonspecific. We examined 23 of the 25 protein 
targets listed in Table 2 for possible associations with other cancer types and/or with 
inflammatory bowel diseases. A review of Polanski and Anderson’s list of 1261 proteins 
reported to be differentially expressed in human cancers (82) indicated that eight of these 
proteins (35% of our protein list) were associated with cancers other than CRC (Table 2). 
FunDO (45) analysis of the genes encoding these 23 candidates revealed six additional proteins 
that were associated with multiple cancers, but not with inflammatory bowel diseases 
(Supplementary Figure 10). These findings indicate that our proteins of interest are not 
associated with inflammation of the digestive tract, however fourteen (56%) of them have links 
to multiple cancers. 
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Carcinoembryonic antigen is the only protein currently used as a circulating biomarker 
for CRC recurrence and metastasis (83). The proteins that were consistently upregulated in our 
colorectal tumors and that distinguished adenoma and/or adenocarcinomas from normal mucosa 
with appreciable sensitivity and specificity (Figures 4 to 6) are promising candidates for use in 
blood-based assays for the detection of these tumors. Some of these proteins have been already 
investigated in other proteomics studies as prognostic serum biomarkers in patients with CRC. 
Elevated serum levels of REG4 and of total LDH, for example, have both proved to be 
significant indicators of liver metastasis in this setting (84, 85), whereas increased serum levels 
of LCN2 are reportedly associated with higher neoplastic volume and disease recurrence (86).  
Our data suggest that the presence in body fluids of S100A11, SERPINB5, NCL, SORD, 
and ANXA3 might be an indication for colonoscopy, although this five-marker signature cannot 
distinguish whether the patient is likely to be harboring an adenoma or an adenocarcinoma. 
Three of these markers have also been reported in blood-based validation studies on CRC. For 
instance, a nine-protein multiplex serum array biochip that includes S100A11 and CEA showed 
high diagnostic potential for colon cancer (87). Serum levels of SERPINB5 have also been 
found to be elevated in patients with colorectal adenoma or CRC (81), and ANXA3 was recently 
validated as a potential diagnostic and therapeutic serum marker for CRC (88).  
The substances secreted in detectable amounts by CRCs also include products of tumor 
metabolism. The analysis of volatile organic compounds is an emerging field in the search for 
noninvasive metabolite tumor-marker profiles (89). Electronic-nose technology and canine and 
Caenorhabditis elegans scent detection have been used to analyze the presence of these 
compounds in breath, urine, and stool samples (89-91) from CRC patients. The reported 
sensitivity and specificity of these approaches in distinguishing between individuals with and 
without CRC or advanced adenomas are comparable to those of conventional colonoscopy 
(>90%) (90, 91). In the present study, we found significantly increased levels of metabolic 
enzymes in the adenomas (SORD, LDHA) and adenocarcinomas (SORD, G6PD, LDHA) we 
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examined. Metabolite products from reactions catalyzed by these enzymes and associated 
pathway enzymes are potential indicators of tumor occurrence. Interestingly, lactate levels in the 
adenomas we examined in (34) were significantly higher in adenomas than in healthy control 
tissue, suggesting that aerobic glycolysis occurs in benign colorectal tumors. 
The potential translational impact of our findings on the future clinical management of 
patients with early colorectal lesions is obvious. However, they can also be exploited to improve 
our understanding of the molecular mechanisms underlying colorectal tumorigenesis. To this 
end, we probed the five proteins that most effectively discriminated between normal mucosa and 
colorectal tumors (Figure 6) for functional relations with the rest of the proteome. Using the 
GeneMANIA tool, we queried association data on protein and genetic interactions, pathways, 
co-expression, co-localization, and protein domain similarity. As shown in Supplementary 
Figure 11, nucleolin (NCL) was the signature protein with the highest number of interactions 
with cancer-related proteins. It directly associates with TERT and TOP1, which are key players 
in oncogenesis (92, 93). TERT mRNA and protein expression occurs early in in vivo colorectal 
tumorigenesis, beginning in the early pre-malignant phase and increasing gradually during 
progression to invasive stages (94). As for TOP1, inhibitors of this enzyme are used as first-line 
chemotherapeutics for CRC (93). The calcium binding protein S100A11 is best described as a 
dual mediator with effects that depend on its localization and interaction partners. It therefore 
functions as a tumor suppressor in some cancers (e.g., those of the breast) and as an oncogene in 
others, including CRC. It interacts directly with NCL, S100B, ANXA1, and UBE2F (95-98) 
(Supplementary figure 11). The peptidase inhibitor, SERPINB5, has also been reported to exert 
tumor-promoting as well as tumor-suppressor effects. Recent protein biomarker studies have 
revealed that elevated SERPINB5 expression in CRCs correlates with high CEA levels and poor 
prognosis (99). SORD was found to physically interact with three proteins: AKR1B1, which—
like SORD—is involved in the polyol pathway; GCLM, and C16orf13 (98). The roles of GCLM 
and C16orf13 in tumorigenesis are unclear. Annexin A3 is a calcium-dependent phospholipid-
 27 
binding protein with potential roles in maintaining cell proliferation and invasion (88). It 
physically interacts with ANXA11 (98). 
In conclusion, SRM allows reproducible, simultaneous detection and quantification of 
multiple proteins in numerous samples. Protein abundance changes in adenomas relative to the 
normal colorectal mucosa are unambiguously indicative of phenotypic alterations present in 
early stage tumors. Our study is limited in regard to the validation of these potential biomarkers 
in serum/plasma of patients undergoing colonoscopic screening, and patients diagnosed with 
adenomas and/or CRC. Future work should assess levels of the proteins we verified in colorectal 
tissue samples in blood samples collected from patients. Efforts of this type will undoubtedly 
reveal additional, related proteins or metabolites with complementary diagnostic attributes that 
might also prove useful in pre-colonoscopic, non-invasive tests for the early diagnosis of 
colorectal tumors.  
 
ADDITIONAL INFORMATION 
The MS/MS data from this study have been submitted to the PeptideAtlas SRM 
Experiment Library (PASSEL) (http://www.peptideatlas.org/passel/). SRM data are available at 
PeptideAtlas SRM Experiment Library (PASSEL) and can be accessed using the identifier 
PASS00900. 
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FIGURE LEGENDS 
Figure 1. Block-randomized experimental design for SRM analysis. Extraction of protein from 
samples was randomized based on the tumor type. Two paired samples (1 consisting of adenoma 
and adjacent normal mucosa, the other of adenocarcinoma and adjacent normal mucosa) were 
extracted at the same time. Enzymatic digestion of protein extracts was performed in three batches, 
each comprising 24 randomly allocated samples. In each batch, one randomly selected matched 
tissue pair (tumor / normal mucosa) was digested twice (duplicates). Transitions for time-
scheduled SRM were divided into two groups, and each sample was analyzed twice according to a 
randomized queue. More details in Experimental Section and Results. 
Figure 2. Targeted quantification of peptide species and proteins. (A) Shaded circles represent the 
number of candidate peptides and proteins selected, identified, and consistently quantified in 
normal and neoplastic lesions. Protein number is indicated with *. (B) The measured data (log 
transformed light/heavy ratio) for the 25 protein targets quantified. Hierarchical clustering with 
uncentered correlation and complete linkage was employed to group samples based on measured 
protein abundance. Tumor samples labeled in light blue are adenocarcinomas; those in dark blue 
are adenomas. Adenoma-paired samples of normal mucosa (adjacent normal adenoma) are labeled 
in orange; carcinoma-paired samples of normal mucosa (adjacent normal carcinoma) are in yellow.  
Figure 3. Quantification of tumor markers in colorectal adenomas (A) and adenocarcinomas (B) 
(relative to matched normal mucosal samples). Proteins with an adjusted P value <0.05 and a fold 
change ≥ ±1.3 were considered significant. Housekeeping proteins monitored in the two time-
scheduled methods are denoted with _1 and _2. 
Figure 4. Predictive power of colorectal adenoma markers. ROC analysis was performed for the 
five proteins most markedly dysregulated in adenomas (selected based on P values). ROC curves 
show the predictive power of each protein to distinguish between adenomas and normal mucosa 
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(left panels). Protein intensities used for ROC analysis are shown in the box plot (right panels). 
NAD; normal mucosa samples, AD: adenomas. 
Figure 5. Predictive power of colorectal adenocarcinoma markers. ROC analysis was performed 
for the five proteins most markedly dysregulated in adenocarcinomas (selected on the basis of P 
values). ROC curves the power of each protein to distinguish between adenocarcinoma and normal 
mucosa (left panels). Protein intensities used for ROC analysis are shown in the box plot (right 
panels). NADC; normal mucosa samples, ADC: adenocarcinomas. 
Figure 6. Potential markers for colorectal tumors (adenoma or adenocarcinoma). ROC analysis 
was performed for the five proteins displaying the highest dysregulation in adenomas and 
adenocarcinomas (ranked according to P values). ROC curves show the power of each protein to 
distinguish between tumors and normal mucosa (upper panel). Protein intensities used for ROC 
analysis are shown in the box plot (lower panels). N; normal mucosa samples, T: adenomas and 
adenocarcinomas 
Figure 7. Correlation between the five-marker protein panel and clinical features of each tumor. 
(A) Linear fit shows the positive correlation between SORD or NCL abundance and lesion 
diameter.  (B). SORD, S100A11 and SERPINB5 were also positively associated with type V pit 
pattern in the neoplastic mucosa. C. Tumor expression of SORD, S100A11, and SERPINB5 was 
higher in adenoma subtypes than in adenocarcinomas (see Table 1). Cancer – adenocarcinomas, 
SSA – sessile serrated adenoma, TA – tubular adenomas, TVA – tubulovillous adenomas, VA – 
villous adenomas. 
Figure 8. Correlation between SRM measurements of target proteins in adenomas in the present 
study and corresponding iTRAQ measurements from our previous study (34). (A) Analysis of the 
average deconvoluted protein ratios (normal mucosa/adenoma) obtained with the two methods 
shows fairly good correlation between the two sets of measurements. P value = 0.000196, 
Pearson’s r = 0.82. (B) Deconvoluted log2 ratio (normal/adenoma) of ARF6 in tumors investigated 
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with iTRAQ and with SRM. ARF protein ratio in matched normal and adenoma samples was 
quantified based on 1) the intensity of the unique peptide consistently quantified in samples in the 
SRM study (SRM 1 unique peptide), 2) the intensity of this same peptide measured in samples 
from the iTRAQ group (iTRAQ 1 unique peptide), and 3) the intensity of all confidently identified 
peptides measured with iTRAQ 8-plex method (iTRAQ all peptides). Protein ratio in adenomas 
and matched normal samples was compared with a paired t test and ^ indicates a significant P 
value (C) ANOVA of fit between ARF6 abundance and tumor pit pattern.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patient 
no. 
Sample 
type/no. ^ Age Sex
Location 
(Colon 
segment)
Maximum 
diameter 
(mm)
Paris 
classification 
# 
Pit patternº
Microscopic 
appearance
Highest 
grade of 
dysplasia ▪ 
Cancer stage/ 
grade º
Lesions excised at 
study  colonoscopy 
∞
Lesions excised 
during prior 
colonoscopy ‡
1 AD-1 50 F C 30 0 - IIa IIIL TA low - 1 1
2 AD-2 72 F A 20 Is IV TVA low - 1 0
3 AD-3 66 F S 35 Ip IV TA low - 1 0
4 AD-4 78 M R 50 IIa + Is IV + Vi TVA low - 1 0
5 AD-5 58 F R 20 IIa + IIc IIIL -Vi TA low - 2 0
6 AD-6 60 M C 30 Is IV TVA low - 2 2
7 AD-7 65 M A 40 IIa + Is IV TA low - 1 0
8 AD-8 70 F R 20 Is + IIa IV TVA low - 1 0
9 AD-9 70 M A 40 Is + IIa IV TA low - 1 0
10 AD-10 77 F R 80 IIa + Is IV VA low - 1 0
11 AD-11 83 M S 20 IIa + Is IIIL TVA low - 3 0
12 AD-12 75 F S 30 IIa + Is IIIL -IV TA low - 1 3
13 AD-13 63 M T 30 0 - Is IV TVA low - 1 0
14 AD-14 74 F A 80 Is + IIa IV TVA low - 1 0
15 AD-15 82 M D 50 Is + IIa IV VA low - 1 0
16 AD-16 61 F R 40 Is + IIa II SSA low - 1 0
17 AD-17 72 F C 45 0 - Is IV TA high - 1 0
18 AD-18 58 M D 20 0 - Ip IV TA high - 2 0
19 AD-19 83 F C 35 Is IV TVA high - 1 0
20 ADC-1 78 M R 60 IIa + Is Vi - IV cancer - NA 1 1
21 ADC-2 58 M S 40 Is IV + Vi cancer - NA 2 1
22 ADC-3 67 F R 40 0 - Is Vn cancer - NA 1 0
23 ADC-4 37 M R 60 0 - Is Vn cancer - NA 1 0
24 ADC-5 63 M S 80 0 - Is Vn cancer - NA 1 0
25 ADC-6 82 M S 65 0 - Is Vn cancer - T2N0M0/G2 1 0
26 ADC-7 52 M S 60 0 - Is Vn cancer - T4N0M0/G2 1 0
27 ADC-8 56 F A 65 0 - Is Vn cancer - NA 1 0
28 ADC-9 55 M R 70 0 - Is Vn cancer - T3N0M0/G2 3 0
29 ADC-10 87 F T 70 0 - Is Vn cancer - T3N0M0/G2 1 0
30 ADC-11 64 F A 60 0 - Is Vn cancer - NA 1 0
31 ADC-12 64 M C 70 Is NA cancer - T2N0M0/G2 1 0
32 ADC-13 88 F A 55 0 - Is Vi cancer - T3N0M0/G2 1 0
33 ADC-14 67 M T 80 0 - Is Vn cancer - T3N1M0/G2 1 0
34 ADC-15 64 M R-S 100 0 - Is Vn cancer - NA 2 1
35 ADC-16 61 F T 60 0 - Is Vn cancer - T3N0M0/G2 1 0
36 ADC-17 53 F A 50 0 - Is Vn cancer - T3N0M0/G2 1 0
‡ Total no. of lesions detected and excised during previous colonoscopies. 
Table 1.  Characteristics of the neoplastic lesions included in the study. 
Abbreviations: AD, adenoma; ADC, adenocarcinoma; C, cecum; A, ascending colon; T, transverse colon;  D, descending colon; S, sigmoid; R, rectum; TA, tubular adenoma; TVA, 
tubulovillous adenoma; VA, villous adenoma;  SSA, sessile serrated adenoma; NA, data not available (as for cancers, staging and grading not available since patient was treated in a 
different hospital).
# Macroscopic appearance classified according to the Paris Endoscopic Classification of Superficial Neoplastic Lesions. Gastrointest. Endosc., 2003; 58, S3-S43. 
º Kudo classification of colon crypt morphology. Kudo S, Rubio CA, Teixeira CR, et al. Pit pattern in colorectal neoplasia:endoscopic magnifying view. Endoscopy 2001; 33, 367-7. 
▪ WHO classification of tumors of the digestive system, editorial and consensus conference in Lyon, France, November 6-9, 1999.IARC.  
∞ Total no. of lesions detected and excised during  the study colonoscopy, including the single lesion used in the proteomics analysis.
º Cancer TNM and grade classification in according to Sobin LH, Wittekind C. TNM classification of malignant tumors. 6th ed. New York, NY: Wiley-Liss, 2002.
^ serial number for AD and ADC lesions
Table 2. SRM-based quantification of target proteins in colorectal adenomas and adenocarcinomas.
Uniprot 
Accession Protein name Gene name
Log2 Fold 
change Fold change
Adjusted P 
value Significant
Trend in 
iTRAQ data 
(ref. 34) 
Log2 Fold 
change Fold change
Adjusted P 
value Significant
Human Plasma 
Proteome              
(Farrah et al., 2011)
Human Plasma Proteome          
(Keshishian et al., 2015) 
Cancer associated 
proteins in (ref. 82)° 
and (ref. 45)^
signalP v4.1 
(ref. 75)
secretomeP v 
2.0a (ref. 76)
Extra-cellular 
vesicles (ref. 77)
P15121 ALDR AKR1B1 0.0 1.03 0.67648        No NS -0.5 1.37 0.00005 Yes     ê Yes Yes Yes ° ^ No No Yes
P39687 AN32A * ANP32A 0.5 1.43 0.00000 Yes     é UP * 0.4 1.35 0.00001 Yes     é Yes Yes No No No Yes
Q92688 AN32B * ANP32B 0.4 1.27 0.00023 No UP * 0.4 1.34 0.00005 Yes     é Yes Yes No No No Yes
P12429 ANXA3 ANXA3 0.9 1.86 0.00000 Yes     é UP 1.4 2.66 0.00000 Yes     é Yes Yes No No No Yes
P27695 APEX1 APEX1 0.1 1.10 0.13701 No UP -0.5 1.40 0.00000 Yes     ê Yes Yes Yes ° ^ No Yes Yes
P62330 ARF6 ARF6 -0.4 1.30 0.00005 Yes     ê UP -0.9 1.93 0.00000 Yes     ê No Yes Yes ^ No Yes Yes
Q00796 DHSO SORD 1.4 2.73 0.00000 Yes     é UP 0.4 1.30 0.00008 Yes     é Yes Yes Yes ° No No Yes
P04406 G3P # GAPDH 0.4 1.34 0.00000 Yes     é NS 0.1 1.05 0.39098 No Yes No No No No Yes
P11413 G6PD G6PD 0.3 1.25 0.05023 No NS 1.1 2.15 0.00000 Yes     é Yes Yes Yes ° No No Yes
P07900 HS90A # HSP90AA1 0.2 1.14 0.08444 No NS 0.3 1.20 0.03215 No No Yes Yes ° No No No
P00338 LDHA * LDHA 1.1 2.10 0.00000 Yes     é UP * 0.9 1.86 0.00000 Yes     é Yes Yes Yes ° No No Yes
P07195 LDHB * LDHB 0.2 1.17 0.03996 No UP * 0.3 1.20 0.02418 No Yes Yes Yes ° No No Yes
P80188 NGAL LCN2 1.1 2.12 0.00000 Yes     é UP 1.4 2.72 0.00000 Yes     é Yes Yes Yes ^ Yes Yes + Yes
P19338 NUCL NCL 1.0 1.98 0.00000 Yes     é UP 0.8 1.69 0.00000 Yes     é No Yes Yes ^ No No Yes
P31949 S10AB S100A11 1.8 3.49 0.00000 Yes     é UP 1.1 2.16 0.00000 Yes     é Yes Yes Yes ^ No Yes Yes
P36952 SPB5 SERPINB5 3.4 10.23 0.00000 Yes     é UP 2.0 3.87 0.00000 Yes     é Yes Yes No No No Yes
Q9UKY7 CDV3 CDV3 0.7 1.59 0.00008 Yes     é UP 0.9 1.85 0.00000 Yes     é Yes Yes No No No Yes
Q15181 IPYR * PPA1 1.0 1.94 0.00000 Yes     é UP * -0.4 1.31 0.00180 Yes     ê No Yes No No No Yes
Q9H2U2 IPYR2 * PPA2 0.4 1.33 0.00014 Yes     é UP * -0.3 1.22 0.01418 No No Yes Yes ° No No Yes
Q96CX2 KCD12 KCTD12 -0.5 1.42 0.00000 Yes     ê DOWN -0.1 1.08 0.32967 No No Yes No No Yes Yes
Q6UX06 OLFM4 OLFM4 0.7 1.58 0.00044 Yes     é UP 0.4 1.36 0.02941 Yes     é No No Yes ^ Yes Yes + Yes
Q15124 PGM5 PGM5 -1.3 2.40 0.00000 Yes     ê DOWN -0.6 1.55 0.00019 Yes     ê No Yes No No No + Yes
Q15293 RCN1 RCN1 0.2 1.16 0.07462 No UP 0.6 1.49 0.00001 Yes     é No Yes No Yes Yes + Yes
Q9BYZ8 REG4 REG4 1.6 2.97 0.00000 Yes     é UP 0.7 1.59 0.00005 Yes     é No Yes No Yes Yes + Yes
Q01105 SET SET -0.1 1.08 0.26687 No UP 0.70 1.62 0.00000 Yes     é Yes Yes Yes ^ No No Yes
* Protein isozymes and isoforms 
# Data from the first method for "housekeeping" proteins measured in both scheduled SRM methods. Datasets obtained with both methods 1 and 2 were identical.
NS: not significant or not detected, UP: upregulated, DOWN: downregulated
 ° Cancer associated proteins listed in Polanski and Anderson (reference 82)
 ^ Cancer associated proteins identified using functional disease ontology annotations (reference 45)
 + Protein has a signal peptide
SignalP cut-off: D-score ≥ 0.45, SecretomeP cut-off: NN-score ≥ 0.6
Extra-cellular vesicles (reference 77): curated proteins in Vesiclepedia detected in microvesicles and exosomes from colorectal cancer cells
Proteins detected in human plasma/serum Proteins secreted via classical and non-classical pathwaysAdenocarcinoma vs. Normal mucosaAdenoma vs. Normal mucosa
Proteins upregulated (é) or downregulated (ê) in colorectal adenomas and/or adenocarcinomas compared to the normal mucosa. Significantly dysregulated proteins met the 
cutoff criteria: fold change ≥1.3, adjusted P value <0.05. 
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